CITIGROUP INC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.

Quarter-by-quarter ownership
CITIGROUP INC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$157,000
-29.9%
133,051
-16.2%
0.00%
Q2 2023$223,867
-67.8%
158,771
-65.7%
0.00%
Q1 2023$694,326
+24.4%
462,884
-3.0%
0.00%
Q4 2022$558,294
+262.5%
477,174
+250.9%
0.00%
Q3 2022$154,000
+1825.0%
135,981
+2657.7%
0.00%
Q2 2022$8,000
-42.9%
4,931
-45.4%
0.00%
Q1 2022$14,000
-83.9%
9,037
-74.6%
0.00%
Q4 2021$87,000
-74.9%
35,607
-74.2%
0.00%
Q3 2021$347,000
+951.5%
137,858
+1082.0%
0.00%
Q2 2021$33,000
+73.7%
11,663
+43.4%
0.00%
Q1 2021$19,000
+90.0%
8,136
+38.1%
0.00%
Q4 2020$10,000
+66.7%
5,8910.0%0.00%
Q3 2020$6,000
+20.0%
5,8910.0%0.00%
Q2 2020$5,000
-83.9%
5,891
-84.1%
0.00%
Q1 2020$31,000
+3.3%
37,110
+8.6%
0.00%
Q4 2019$30,000
+100.0%
34,175
+119.1%
0.00%
Q3 2019$15,00015,5980.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders